These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 28166803

  • 1. A novel monoclonal antibody against the von Willebrand Factor A2 domain reduces its cleavage by ADAMTS13.
    Zhang L, Su J, Shen F, Ma Z, Zhao Y, Xia L, Ruan C.
    J Hematol Oncol; 2017 Feb 06; 10(1):42. PubMed ID: 28166803
    [Abstract] [Full Text] [Related]

  • 2. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.
    Rauch A, Legendre P, Christophe OD, Goudemand J, van Belle E, Vincentelli A, Denis CV, Susen S, Lenting PJ.
    Thromb Haemost; 2014 Nov 06; 112(5):1014-23. PubMed ID: 25030452
    [Abstract] [Full Text] [Related]

  • 3. A conformation-sensitive monoclonal antibody against the A2 domain of von Willebrand factor reduces its proteolysis by ADAMTS13.
    Zhang J, Ma Z, Dong N, Liu F, Su J, Zhao Y, Shen F, Wang A, Ruan C.
    PLoS One; 2011 Nov 06; 6(7):e22157. PubMed ID: 21779388
    [Abstract] [Full Text] [Related]

  • 4. Blood group antigen A on von Willebrand factor is more protective against ADAMTS13 cleavage than antigens B and H.
    Hayakawa M, Kato S, Matsui T, Sakai K, Fujimura Y, Matsumoto M.
    J Thromb Haemost; 2019 Jun 06; 17(6):975-983. PubMed ID: 30929293
    [Abstract] [Full Text] [Related]

  • 5. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.
    Pruss CM, Notley CR, Hegadorn CA, O'Brien LA, Lillicrap D.
    Br J Haematol; 2008 Nov 06; 143(4):552-8. PubMed ID: 18986390
    [Abstract] [Full Text] [Related]

  • 6. [Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13].
    Zhang JY, Su J, Ma ZN, Dong NZ, Wang YC, Ruan CG.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar 06; 33(3):169-72. PubMed ID: 22781599
    [Abstract] [Full Text] [Related]

  • 7. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1.
    Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL.
    Blood; 1997 Mar 15; 89(6):1954-62. PubMed ID: 9058716
    [Abstract] [Full Text] [Related]

  • 8. Prediction of spacer-α6 complex: a novel insight into binding of ADAMTS13 with A2 domain of von Willebrand factor under forces.
    Fang X, Lin J, Fang Y, Wu J.
    Sci Rep; 2018 Apr 10; 8(1):5791. PubMed ID: 29636514
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation.
    Muia J, Zhu J, Greco SC, Vanhoorelbeke K, Gupta G, Westfield LA, Sadler JE.
    Blood; 2019 Apr 25; 133(17):1899-1908. PubMed ID: 30700419
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate.
    Cruz MA, Whitelock J, Dong JF.
    Thromb Haemost; 2003 Dec 25; 90(6):1204-9. PubMed ID: 14652658
    [Abstract] [Full Text] [Related]

  • 12. The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity.
    Daidone V, Saga G, Barbon G, Pontara E, Cattini MG, Morpurgo M, Zanotti G, Casonato A.
    Br J Haematol; 2015 Aug 25; 170(4):564-73. PubMed ID: 25904363
    [Abstract] [Full Text] [Related]

  • 13. ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation.
    Deconinck SJ, Nix C, Barth S, Bennek-Schöpping E, Rauch A, Schelpe AS, Roose E, Feys HB, Pareyn I, Vandenbulcke A, Muia J, Vandenbriele C, Susen S, Meyns B, Tersteeg C, Jacobs S, De Meyer SF, Vanhoorelbeke K.
    J Thromb Haemost; 2022 Dec 25; 20(12):2797-2809. PubMed ID: 36128768
    [Abstract] [Full Text] [Related]

  • 14. Crystal structure and substrate-induced activation of ADAMTS13.
    Petri A, Kim HJ, Xu Y, de Groot R, Li C, Vandenbulcke A, Vanhoorelbeke K, Emsley J, Crawley JTB.
    Nat Commun; 2019 Aug 22; 10(1):3781. PubMed ID: 31439947
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mutation G1629E Increases von Willebrand Factor Cleavage via a Cooperative Destabilization Mechanism.
    Aponte-Santamaría C, Lippok S, Mittag JJ, Obser T, Schneppenheim R, Baldauf C, Gräter F, Budde U, Rädler JO.
    Biophys J; 2017 Jan 10; 112(1):57-65. PubMed ID: 28076816
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD.
    Kizlik-Masson C, Peyron I, Gangnard S, Le Goff G, Lenoir SM, Damodaran S, Clavel M, Roullet S, Regnault V, Rauch A, Vincent F, Jeanpierre E, Dupont A, Ternisien C, Donnet T, Christophe OD, van Belle E, Denis CV, Casari C, Susen S, Lenting PJ.
    Blood; 2023 Mar 23; 141(12):1457-1468. PubMed ID: 36564031
    [Abstract] [Full Text] [Related]

  • 19. [Identification of Monoclonal Antibodies against von Willebrand Factor Cleaving Protease (ADAMTS13) and Their Function].
    Ma ZN, Ling J, Shen F, Xie LQ, Yin J, Su J, Ruan CG.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug 23; 24(4):1104-9. PubMed ID: 27531783
    [Abstract] [Full Text] [Related]

  • 20. Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.
    Kubo M, Sakai K, Hayakawa M, Kashiwagi H, Yagi H, Seki Y, Hasegawa A, Tanaka H, Amano I, Tomiyama Y, Matsumoto M.
    J Thromb Haemost; 2022 Jul 23; 20(7):1589-1598. PubMed ID: 35352474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.